Quality & Compliance
Safety & Vigilance
25 july 2023
In the dynamic and ever-evolving landscape of pharmaceuticals, ensuring patient safety and monitoring medication effectiveness is paramount. Pharmacovigilance, the science and activities related to detecting, assessing, understanding, and preventing adverse effects or other drug-related problems, plays a vital role in safeguarding public health. At the core of pharmacovigilance is the Qualified Person for Pharmacovigilance (QPPV), a pivotal figure responsible for overseeing compliance with regulations and guidelines. This article will shed light on the importance of compliance by the QPPV and its role in upholding patient safety.
The QPPV serves as a designated individual within a pharmaceutical company entrusted with ultimate responsibility for the safety of medicinal products. Their primary duty is to ensure that pharmacovigilance activities comply with legal and regulatory requirements, both at national and international levels. The QPPV acts as a liaison between the company and regulatory authorities, maintaining open communication channels for reporting and managing adverse drug reactions. Key performance indicators (KPIs) are measurable values that reflect the effectiveness and efficiency of specific organisational activities. In the context of pharmacovigilance, KPIs provide valuable insights into the performance of safety-related processes and systems. They serve as quantifiable benchmarks against which the success and effectiveness of pharmacovigilance operations can be evaluated. By monitoring KPIs, the QPPV can identify areas of improvement, measure compliance with regulations, and ensure the timely detection and response to adverse events.
Monitoring KPIs is essential for assessing the effectiveness of pharmacovigilance activities. By tracking specific metrics such as the number of adverse event reports received, the timeliness of report submission, and the quality of case processing, the QPPV can evaluate the efficiency of the pharmacovigilance system. KPI monitoring enables the identification of bottlenecks, inefficiencies, or gaps in processes, which can then be addressed to enhance the overall effectiveness of pharmacovigilance activities. The QPPV can ensure that adverse events are captured, evaluated, and acted upon promptly and appropriately by optimising workflows and streamlining processes. KPI monitoring is vital in successfully implementing Risk Management Plans (RMPs). The QPPV, in collaboration with cross-functional teams, establishes specific KPIs to measure the effectiveness of risk management activities outlined in the RMP. These KPIs may include the completion of safety-related milestones, adherence to risk minimisation measures, timely reporting of safety data, and compliance with regulatory requirements. By monitoring these KPIs, the QPPV can assess the progress of risk management activities, identify areas for improvement, and ensure that appropriate measures are implemented to minimise potential risks.
Effective monitoring of KPIs allows the QPPV to identify trends and patterns in adverse event reporting. By analysing data regularly, they can detect emerging safety signals, unusual clusters of adverse events, or changes in the safety profile of medicinal products. These insights enable proactive risk assessment and management, promptly addressing potential safety concerns. KPI monitoring can also facilitate the identification of specific patient populations or concomitant medications that may be associated with higher risks, leading to targeted risk minimisation strategies.
Pharmacovigilance is subject to a complex framework of regulations and guidelines. Monitoring KPIs enables the QPPV to assess the compliance of pharmacovigilance operations with these requirements. KPIs related to report submission timelines, completeness of safety reports, and adherence to labelling requirements ensure that the company meets its legal obligations. By monitoring KPIs, the QPPV can identify deviations or non-compliance issues, allowing corrective actions to be implemented promptly. Moreover, KPI monitoring serves as a tool for quality assurance, ensuring that high standards are maintained throughout the pharmacovigilance processes.
KPI monitoring is instrumental in driving continuous improvement within pharmacovigilance activities. By establishing baseline metrics and tracking performance over time, the QPPV can measure the impact of process changes, training initiatives, or new technologies to enhance pharmacovigilance operations. This data-driven approach facilitates evidence-based decision-making and supports resource allocation to areas that require improvement. KPI monitoring also enables benchmarking against industry standards, enabling the QPPV to compare their organisation’s performance with that of peers and identify areas where further improvement is necessary.
The pharmaceutical industry is subject to a myriad of complex regulations, making compliance a critical aspect of operations. The QPPV is responsible for staying updated with the evolving regulatory landscape and ensuring the company adheres to applicable laws. Compliance encompasses various aspects, including timely submission of safety reports, compliance with labelling requirements, adherence to good pharmacovigilance practices (GVP), and effective risk management strategies. Compliance with regulatory requirements is paramount in pharmacovigilance. KPI monitoring allows the QPPV to ensure compliance with these obligations in both RMPs and signal management. KPIs related to regulatory reporting timelines, completeness of safety reports, adherence to risk minimisation measures, and compliance with guidelines enable the QPPV to assess and maintain compliance with regulatory requirements. By monitoring these KPIs, the QPPV can promptly identify deviations or non-compliance issues and take corrective actions to ensure adherence to regulatory obligations.
Pharmacovigilance is not solely about detecting and reporting adverse events; it also involves proactively managing risks associated with medicinal products. The QPPV is pivotal in devising and implementing risk management plans to minimise potential patient harm. Compliance with risk management requirements ensures that appropriate measures, such as additional safety monitoring or restricted access programs, are in place to mitigate potential risks. By tracking KPIs such as the effectiveness of risk minimisation measures, the impact on patient behaviour, and the success of educational initiatives, the QPPV can assess the outcomes and effectiveness of implemented strategies. By diligently monitoring the safety profile of medicinal products, the QPPV contributes to informed decision-making processes for healthcare professionals and regulatory authorities.
The foremost objective of the QPPV is to safeguard patient safety by overseeing compliance with pharmacovigilance practices. By adhering to established guidelines and regulations, the QPPV plays a pivotal role in maintaining the integrity and quality of the pharmaceutical products reaching the market. This involves implementing robust systems for detecting, collecting, assessing, and reporting adverse events, ensuring that any potential risks associated with medicinal products are identified promptly and acted upon to minimise patient harm. The diligent monitoring of KPIs in RMPs and signal management directly enhances patient safety and maintains public trust.
Compliance is an essential aspect of pharmacovigilance and the QPPV’s role in ensuring compliance cannot be overstated. By upholding regulatory requirements, safeguarding patient health, ensuring quality and consistency, facilitating effective risk management, and building trust, the QPPV plays a pivotal role in protecting patient safety and maintaining regulatory standards. Compliance is the foundation on which a robust pharmacovigilance system is built, and it is through these efforts that the pharmaceutical industry continues to prioritise patient well-being.
PLG’s Global Support: Centralising resources to better serve our clients.
In the EU, the QPPV and LQPPV are important figures in adhering to the compliance standards set out by the Health Authorities. PLG’s international market analysis has identified this as a growing global trend. Recognising these trends has allowed us to distribute our pharmacovigilance resources worldwide strategically.
ProductLIfe now covers the major pharmaceutical markets in providing QPPVs and LQPPVs where obligated. We have followed up on this provision with macro-outsourcing services, including Case Processing, Medical Information, Local and Global Literature Search and Medical Writing.
When you want to centralise your PV services, contact PLG to learn how we can support you.
Go to our Events to register
Go to our News to get insights